Treatment outcomes according to the EndoPredict score in ER-positive, HER2-negative early breast cancer

Purpose: To evaluate the treatment outcomes of estrogen receptor-positive/human epidermal growth factor receptor 2-negative(ER+/HER2 −) breast cancer according to the risk group using EndoPredict(EP) score. Patients and Methods: Between 2015 and 2019, 207 patients with ER+/HER2− pN0-N1 early breast cancer who underwent surgery, EP test, and adjuvant radiotherapy were accrued. EPclin score, which combines the molecular EP scor e with nodal status and tumor size, was calculated, and patients were divided into EPclin low- or high-risk groups by the cutoff value of 3.3. Results: There were 154 and 53 patients in the EPclin low- and high-risk groups, respectively. Forty-one patients(81.1%) of the high-risk group received adju vant chemotherapy, while only 1(0.6%) of the low-risk group did. With a median follow up of 54.1 months(range 8.2−76.6), the 5-year disease-free survival rates of low- and high-risk groups were 100% and 88.9%, respectively(p
Source: Breast Care - Category: Cancer & Oncology Source Type: research